Scorpion Therapeutics Stock

www.scorpiontx.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $420.47MM

Scorpion Therapeutics is an oncology company focused on transforming cancer treatment through an approach that offers precise selectivity and efficacy for oncology patients. Scorpion Therapeutics was founded in 2020 and is headquartered in Boston, MA. The company uses its proprietary technology platform that integrates cancer biology, medicinal chemistry, and data sciences for a holistic approach. The platform aims to allow Scorpion Therapeutics to create highly selective small-molecule compounds that target a broad spectrum of cancer drivers.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Scorpion Therapeutics, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation
Private Market Pricing DetailsValuation & Financings

Enterprise Value

Powered by Forge Data

Access Scorpion Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Animation displayed is not current and securities are shown for illustrative purposes only.

Scorpion Therapeutics Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Scorpion Therapeutics Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Scorpion Therapeutics investors also invested in these private companies

Lightspeed Venture Partners
Citadel Enterprise Americas
Mass General Brigham Ventures
Hillhouse Investment Group

Leadership & Board

Leadership

Liron Bar-Peled Ph.D
Co-Founder
Keith Flaherty MD
Co-Founder
Gaddy Getz Ph.D
Co-Founder
Gary D. Glick Ph.D
Co-Founder
Adam Friedman MD, Ph.D
Chief Executive Officer
Natasja Brooijmans Ph.D
Senior Vice President of Chemical Data Science
Mark Chao MD, Ph.D
Chief Medical Officer
Andrew Fedder
General Counsel
Angel Guzman-Perez Ph.D
Executive Vice President, Head of Chemistry
Erica L. Jackson Ph.D
Chief Discovery Officer
Valerie Jaiswal
Executive Vice President, Finance
Gregory V. Kryukov Ph.D
Vice President of Data Science
Brent Martin Ph.D
Vice President, Head of Chemical Biology
Brian Piper
Chief Financial Officer
Darrin Stuart Ph.D
Chief Scientific Officer
Amanda Valentino
Chief People Officer

Board

Shelley Chu MD, Ph.D
Lightspeed Venture Partners
Jean-François Formela MD
Atlas Venture
Arjun Goyal MD
Vida Ventures
Oleg Nodelman
EcoR1 Capital
Otello Stampacchia Ph.D
Omega Funds

Scorpion Therapeutics stock FAQs

plusminus

Can you buy Scorpion Therapeutics stock?

As Scorpion Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Scorpion Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Scorpion Therapeutics stock?

To invest in a private company like Scorpion Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Scorpion Therapeutics stock?

Yes, you may sell the Scorpion Therapeutics stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Scorpion Therapeutics stock?

If you hold private company shares of Scorpion Therapeutics – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Scorpion Therapeutics on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Scorpion Therapeutics a public company?

No, Scorpion Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Scorpion Therapeutics’ stock price?

Scorpion Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Scorpion Therapeutics private market stock price with Forge Data.
plusminus

What is Scorpion Therapeutics’ stock ticker symbol?

Scorpion Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Scorpion Therapeutics’ news and media highlights

In a series C funding round led by Frazier Life Sciences and Lightspeed Venture Partners, Scorpion Therapeutics raised $150 million.
Updated on: Oct 14, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price™ may rely on a very limited number of inputs in its calculation. Forge Price™ is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price™, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price™. Forge Price™ is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price™ is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price™ for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.